8.2 Osteoarthritis, Gout & Hyperuricemia

Osteoarthritis, Gout & Hyperuricemia

Executive Summary: Osteoarthritis (OA) and gout represent two of the most prevalent and debilitating rheumatologic disorders encountered in ambulatory care. The American College of Rheumatology (ACR) guidelines emphasize evidence-driven pharmacotherapy hierarchies: for osteoarthritis, topical NSAIDs represent the first-line standard for knee OA, minimizing systemic gastrointestinal, cardiovascular, and renal toxicities associated with oral NSAIDs. For gout, clinical mastery centers on the acute termination of inflammatory flares within 24 hours, followed by long-term treat-to-target (T2T) Urate-Lowering Therapy (ULT) aiming for a serum uric acid (SUA) < 6.0 mg/dL (or < 5.0 mg/dL in tophaceous disease). Ambulatory pharmacists play a pivotal role in performing pre-allopurinol HLA-B*5801 pharmacogenomic screening, titrating xanthine oxidase inhibitors, and co-prescribing mandatory anti-inflammatory prophylaxis to suppress mobilization flares.

1. 2019 ACR Guidelines for the Management of Osteoarthritis (OA)

Osteoarthritis is a whole-joint disease characterized by progressive breakdown of articular cartilage, subchondral bone remodeling, osteophyte formation, and low-grade synovial inflammation. It primarily affects weight-bearing joints (knees, hips) and hands (distal interphalangeal [DIP], proximal interphalangeal [PIP], and 1st carpometacarpal [CMC] joints).

Non-Pharmacological Foundations (Core First-Line for All OA)

• Strongly Recommended: Aerobic and resistance exercise, aquatic exercise, weight loss (for knee and hip OA; achieving ≥5% to 10% weight loss produces profound biomechanical joint unloading and symptomatic relief), self-efficacy and self-management programs, tai chi, cane use (held in the hand contralateral to the affected joint), and tibiofemoral knee braces.
• Conditionally Recommended Against: Acupuncture, Transcutaneous Electrical Nerve Stimulation (TENS), modified shoes, and lateral/medial wedge insoles.

Pharmacological Hierarchy in Osteoarthritis

2. Systemic NSAID Risk Stratification: GI, Renal & Cardiovascular Safety

When oral NSAIDs are indicated for OA or musculoskeletal pain, the ambulatory pharmacist must systematically assess three major organ toxicity domains:

                               ORAL NSAID MULTI-ORGAN TOXICITY TRIAGE
                               
        ┌───────────────────────────────────┼───────────────────────────────────┐
        ▼                                   ▼                                   ▼
[ Gastrointestinal Risk ]           [ Cardiovascular Risk ]             [ Renal & Hemodynamic Risk ]
• Moderate Risk: Age >65, high      • All NSAIDs increase MI, stroke,   • Blocks COX-1/2 PGE2 / PGI2
  dose, history of uncomplicated      and Heart Failure exacerbations.  • Loss of compensatory afferent
  ulcer, concurrent ASA/anticoag.   • Boxed Warning for all NSAIDs.       arteriolar vasodilation.
  ──> Add daily PPI or Misoprostol. • Naproxen has lowest thrombotic    • Induces acute GFR decline,
• High Risk: Prior ulcer bleeding     CV risk (PRECISION trial: low-      fluid retention, hypertension,
  ──> Celecoxib + PPI, or avoid.      dose celecoxib comparable).         and hyperkalemia.
                                    • Strictly AVOID in NYHA III-IV     • Strictly AVOID in severe
                                      heart failure or post-CABG.         CKD (eGFR <30 mL/min).

1. Gastrointestinal Toxicity Mitigation

• Mechanism: Non-selective NSAIDs inhibit COX-1, depleting mucosal prostaglandin $E_2$ ($PGE_2$) and prostacyclin ($PGI_2$), leading to decreased gastric mucus secretion, reduced bicarbonate production, diminished mucosal blood flow, and direct epithelial injury.
• Moderate GI Risk Strategy: Co-prescribe a Proton Pump Inhibitor (PPI) (e.g., omeprazole 20 mg daily) or misoprostol with a non-selective NSAID, or utilize a COX-2 selective inhibitor (celecoxib, meloxicam).
• High GI Risk Strategy: Utilize Celecoxib PLUS a PPI, or avoid oral NSAIDs entirely in favor of topical NSAIDs or non-systemic modalities.

2. Cardiovascular Toxicity Nuances

• Mechanism: Selective COX-2 inhibition decreases endothelial prostacyclin ($PGI_2$, a potent vasodilator and platelet aggregation inhibitor) without inhibiting platelet COX-1-derived thromboxane $A_2$ ($TXA_2$, a vasoconstrictor and platelet activator), creating a pro-thrombotic state.
• Comparative Safety: Naproxen (up to 500 mg BID) exhibits the most neutral cardiovascular thrombotic profile due to sustained platelet COX-1 inhibition throughout its 12-hour dosing interval. The landmark PRECISION trial demonstrated that moderate-dose Celecoxib (100–200 mg daily) was non-inferior to naproxen and ibuprofen regarding composite cardiovascular safety (MACE). However, all systemic NSAIDs induce sodium/water retention and can precipitate acute decompensated heart failure.

3. Renal Toxicity & Drug Interactions

• Hemodynamic AKI: In states of decreased effective circulating arterial volume (CKD, heart failure, cirrhosis, volume depletion, ACEi/ARB therapy), glomerular filtration is maintained by prostaglandin-mediated afferent arteriolar vasodilation. NSAIDs constrict the afferent arteriole, precipitating acute prerenal azotemia.
• The "Triple Whammy": Combining an ACE inhibitor or ARB + Diuretic + NSAID drastically increases the incidence of acute kidney injury (AKI) by concurrently lowering afferent perfusion, promoting efferent dilation, and inducing volume depletion.

3. Pathophysiology of Gout & 2020 ACR Diagnostic Criteria

Gout is an intensely painful inflammatory arthritis triggered by the crystallization of monosodium urate (MSU) in synovial fluid and periarticular tissues when serum uric acid (SUA) concentrations exceed the physiological saturation threshold (> 6.8 mg/dL at normal body temperature and pH).

Pathophysiologic Mechanisms

1. Hyperuricemia Etiology: Uric acid is the end-product of purine degradation catalyzed by the enzyme xanthine oxidase: $\text{Hypoxanthine} \\xrightarrow{\text{Xanthine Oxidase}} \text{Xanthine} \\xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid}$
   • Underexcretion (~90% of patients): Impaired renal tubular clearance of uric acid mediated by transporters including URAT1 (SLC22A12) and GLUT9 (SLC2A9).
   • Overproduction (~10% of patients): Excessive purine intake (red meat, organ meats, shellfish, high-fructose corn syrup, beer/alcohol) or high cell turnover (myeloproliferative disorders, chemotherapy tumor lysis, psoriasis).
2. NLRP3 Inflammasome Activation: Phagocytosis of MSU crystals by synovial macrophages triggers the NLRP3 inflammasome complex, activating caspase-1 to cleave and release massive quantities of Interleukin-1 beta (IL-1β), recruiting waves of neutrophils and causing severe acute inflammation.
3. Definitive Diagnosis: Arthrocentesis with polarized light microscopy demonstrating intracellular, negatively birefringent, needle-shaped monosodium urate crystals (appearing bright yellow when parallel to the compensating filter axis).

4. Acute Gout Flare Pharmacotherapy

Therapy for an acute gout flare must be initiated within 24 hours of symptom onset for optimal efficacy. Anti-inflammatory regimens must be continued until the flare completely resolves.

Critical Clinical Rule — Never Hold Baseline ULT: If a patient experiences an acute gout flare while already taking urate-lowering therapy (allopurinol, febuxostat), CONTINUE the baseline ULT without interruption or dose modification. Discontinuing ULT causes dramatic fluctuations in serum uric acid, prolonging and worsening the flare.

First-Line Monotherapy Regimens for Acute Gout Flares

Colchicine Drug-Drug Interactions & Severe Toxicities

• Mechanism: Binds tubulin to inhibit microtubule polymerization, preventing neutrophil chemotaxis, adhesion, and phagocytosis.
• CYP3A4 and P-Glycoprotein (P-gp) Boxed Warning: Colchicine is a major substrate of both CYP3A4 and P-gp. Co-administration with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) or strong P-gp inhibitors (cyclosporine) in patients with renal or hepatic impairment can cause fatal colchicine toxicity, characterized by severe bone marrow suppression, agranulocytosis, neuromyopathy, and rhabdomyolysis.

5. Chronic Treat-to-Target (T2T) Urate-Lowering Therapy (ULT)

Urate-lowering therapy reduces serum uric acid below the saturation point, dissolving existing crystal deposits, resolving tophi, preventing future flares, and halting joint damage.

ACR Indications for Initiating ULT

                               ACR INDICATIONS FOR INITIATING ULT
                               
      [ STRONGLY RECOMMENDED ]                             [ CONDITIONALLY RECOMMENDED ]
      Initiate ULT in ANY patient with:                   Consider ULT in patients with:
      1. ≥ 1 Subcutaneous Tophus (tophi)                  • Infrequent flares (<2/year) BUT with:
      2. Radiographic joint damage attributable to gout      - CKD Stage ≥ 3 (eGFR <60 mL/min)
      3. Frequent gout flares (≥ 2 flares per year)          - Serum Uric Acid > 9.0 mg/dL
                                                             - History of Urolithiasis (kidney stones)
                                                             
      [ CONDITIONALLY AGAINST ] ──> Asymptomatic Hyperuricemia (SUA >6.8 with NO flares or tophi)

Treat-to-Target (T2T) Serum Uric Acid Goals

• Standard Target: Maintain serum uric acid < 6.0 mg/dL (360 µmol/L) for all patients receiving ULT.
• Tophi / Severe Erosive Gout Target: Maintain serum uric acid < 5.0 mg/dL (300 µmol/L) to accelerate crystal dissolution until all tophi have completely resolved.

First-Line & Alternative Urate-Lowering Medications

6. Pharmacogenomics of Allopurinol & Mandatory Flare Prophylaxis

HLA-B*5801 Pharmacogenomic Screening

• The Clinical Risk: The HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) and Severe Cutaneous Adverse Reactions (SCAR), encompassing Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). AHS carries a mortality rate of 20% to 25%.
• Mandatory Pre-Screening Populations: The 2020 ACR guidelines strongly recommend testing for the HLA-B*5801 allele prior to initiating allopurinol in:
  1. Patients of Southeast Asian descent with high allele frequency (Han Chinese, Korean, Thai ancestry).
  2. African American patients (who exhibit higher population allele frequencies and higher rates of severe allopurinol-induced cutaneous toxicity than Caucasian populations).
• Actionable Rule: If the patient tests positive for HLA-B*5801, allopurinol is strictly contraindicated. Use febuxostat as the alternative first-line xanthine oxidase inhibitor.

Critical Xanthine Oxidase Inhibitor Drug Interaction: Azathioprine & 6-Mercaptopurine

• Both allopurinol and febuxostat potently inhibit xanthine oxidase, the primary metabolic pathway for azathioprine and 6-mercaptopurine (6-MP).
• Lethal Toxicity: Co-administration leads to massive accumulation of 6-thioguanine nucleotides, causing life-threatening, fatal pancytopenia and severe bone marrow aplasia.
• Clinical Action: If an XOI must be co-administered with azathioprine or 6-MP, the dose of azathioprine/6-MP MUST be reduced by 67% to 75% (to 25%–33% of the original dose), with frequent CBC monitoring.

Mandatory Anti-Inflammatory Flare Prophylaxis During ULT Initiation

• The Paradoxical Flare Phenomenon: Initiating or titrating any urate-lowering therapy causes rapid dissolution and remodeling of articular MSU crystal deposits, shedding microcrystals into the synovial space and precipitating acute, severe "mobilization flares". Mobilization flares represent the #1 cause of early patient non-adherence and ULT discontinuation.
• ACR Prophylaxis Regimens:
  1. Colchicine 0.6 mg PO once daily or BID (preferred first-line; adjust for renal function/CYP3A4 inhibitors).
  2. Low-dose NSAID (e.g., Naproxen 250 mg PO BID) co-prescribed with a gastroprotective PPI.
  3. Low-dose Prednisone ($\le 10 ext{ mg PO daily}$) if colchicine and NSAIDs are contraindicated.
• Duration of Prophylaxis: Prophylaxis must be continued for at least 3 to 6 months after achieving target serum uric acid (<6.0 mg/dL), or continued for 6 months if subcutaneous tophi are present (or until all tophi have completely resolved).